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Local treatment of Dacron patch graft
contaminated with Staphylococcus aureus with
antibiotic-releasing porous apatite ceramic: An
experimental study in the rabbit
Tetsu Sago, MD,a Yoshio Mori, MD, PhD,a Hisato Takagi, MD, PhD,a Hisashi Iwata, MD, PhD,a
Katsutoshi Murase, MD,a Yoshiaki Kawamura, MD, PhD,b and Hajime Hirose, MD, PhD,a Gifu, Japan
Objective: The purpose of this study was to investigate whether or not infection of prosthetic vascular graft could be
prevented with the placement of antibiotic-loaded porous apatite ceramic on the graft with bacterial contamination.
Methods: Teicoplanin as an antibiotic was loaded into a -tricalcium phosphate (TCP) block of porous apatite ceramic.
The activity of teicoplanin released from teicoplanin-loaded TCP was examined for 40 days at 2-day intervals. In an in
vivo study, the graft was patched in the abdominal aorta of a rabbit. Two different doses of Staphylococcus aureus were
applied (n 13). Teicoplanin-loaded TCP was placed around the graft infected with S aureus (n 6). The graft, the tissue
around it, and the arterial blood were collected and cultivated 4 weeks after operation.
Results: The activity of teicoplanin in the replaced saline solution was maintained for at least 40 days. Because graft
infection was established in all rabbits with a dose of 2  107 colony forming units, this dose was used as the dose of S
aureus in this study. Fifty-seven percent of the subjects died from the infection. When teicoplanin-loaded TCP was placed
around the graft contaminated with S aureus, no rabbits died. Bacterial cultures of the graft and of tissues around it were
negative in all rabbits killed 4 weeks after operation. This infection was prevented with teicoplanin-loaded TCP in all
rabbits.
Conclusion: Teicoplanin-loaded TCP may be useful in avoiding Dacron graft infection with S aureus in rabbits. (J Vasc
Surg 2003;37:169-74.)
The reported incidence rate of prosthetic graft infec-
tion is 1% to 6%,1,2 but problems are still left to be solved as
far as its treatment is concerned. The most common cause
of graft infection is microorganism contamination of the
graft during implantation or in the perioperative period.3
On the other hand, antibiotic-bonding vascular
graft,4-6 multivesicular liposome-encapsulated amikacin,7
biodegradable amikacin microspheres,8,9 gentamicin with
collagen sponge (GCS),10,11 and gentamicin beads12-15
have been reported as one of drug delivery system (DDS),
in addition to simple local antibiotic administration. How-
ever, problems exist regarding their sustainability and bio-
degradability. Therefore, we examined experimentally
whether or not infection of graft can be prevented with
placement of antibiotic-loaded porous apatite ceramic16
that has relatively high compatibility with the tissue and
that is capable of releasing antibiotics slowly in a longer




Staphylococcus aureus (Gifu 12173) was used as the
infecting organism. The S aureus was obtained from a
patient at the Gifu University Hospital and was penicillin
and methicillin sensitive. It was incubated overnight on
sheep blood agar. Numbers of bacteria were determined
with turbidimetry and were reconfirmed with the culture.
Antibiotics
Teicoplanin (Aventis Pharma S. A., Strasbourg,
France) was used.17
Porous apatite ceramics
-Tricalcium phosphate block (TCP; Ca3[PO4]2;
Olympus Co, Ltd, Tokyo, Japan) with the following prop-
erties was used: porosity, 75%; pore size, 100 to 400m;
average weight, 0.5 g; and shape, arch form with 14 mm
outside diameter, 5 mm inside diameter, and 10 mm high.
With this TCP as the carrier, a sustained release test and an
animal experiment were carried out.
Graft material
Gelatin-sealed knitted Dacron (Gelseal, Vasctek Lim-
ited, Renferewshire, United Kingdom) was used as a patch
and was ellipsoid (5  3 mm) in shape.
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Male Japanese white rabbits (2.5 kg; Chubu Kagaku
Shizai Co, Ltd, Nagoya, Japan) were used.
Minimum inhibitory concentration (MIC) of
teicoplanin for S aureus strain
The MIC of teicoplanin for the S aureus was examined
with an E test18 (Asuka Junyaku Co, Ltd, Tokyo, Japan).
In vitro study of slow release of antibiotics
Stability of teicoplanin in aqueous solution. For
confirmation of the stability of teicoplanin in aqueous
solution, the rate of remaining activity was examined. Ac-
tivity was measured with microbiologic assay according to
the activity measuring method of Minimum Requirements
for Antibiotic Products of Japan. On Mu¨ller-Hington me-
dium, the size of growth inhibition circle at 1 108 colony
forming units (CFUs) of S aureus was obtained with the
disc method and calibration curves were plotted for the
circle sizes versus concentrations of antibiotics on days 0, 3,
7, 14, 21, and 28. With the diameter on day 0 as 100%,
changes of the activity of teicoplanin after dissolution were
examined.19,20
Preparation of TCP. TCP was prepared with the
vacuum method that Itokazu et al16,21,22 reported. In 5.5
mL of teicoplanin solution (180 mg/mL), TCP, 0.5 g in
average, was soaked and exposed to a reduced pressure of
10 in Hg (254 mm Hg) for 20 minutes in a decompressing
chamber, and TCP was loaded with teicoplanin. Teicopla-
nin content in TCP was calculated with measurement of
weight increase.16
In vitro slow releasing test. Teicoplanin-loaded TCP
prepared with the previously mentioned method was put in
2 mL of fresh saline solution and stored in a constant
temperature bath at 37° C. The total amount of saline
solution in the container was replaced at 2-day intervals,
and concentration of teicoplanin released into the saline
solution was measured for 40 days with the Fluorescence
Polarization Immunoassay.19-23 Moreover, the minimum
concentration of teicoplanin in measurement with Fluores-
cence Polarization Immunoassay was 4 g/mL.
In vivo study on infection of a patch graft
Animal preparation. Each rabbit (2.5 kg) was anes-
thetized intramuscularly with ketamine hydrochloride (100
mg/mL) at a dose 0.6 mL/kg. The rabbits were intubated
with an endotracheal tube and were placed in a supine
position after sterilization of the abdominal wall. The rab-
bits were mechanically ventilated. Anesthesia was main-
tained with pentobarbiturate NaCl at a dose of 0.6 mg/kg
intravenously and with pancuronium bromide at a dose of
0.8 mg/kg intravenously. The aorta was approached trans-
peritoneally through a midabdominal incision. The aorta
was cross clamped above and below the patch suturing
region, and a 5  3-mm graft was patched in the anterior
wall of the abdominal aorta at 4 cm distal to the right renal
artery with 6/0 polypropylene suture. Cross-clamp time
was shorter than 30 minutes, and any rabbit that showed
postoperative paraplegia, especially in the early stage of this
experiment, was excluded from this study. The posterior
peritoneum was closed with 4/0 polypropylene suture.
Heparin was not administered during the operation, and
systemic administration of antibiotics was not performed
during the operation or in the perioperative period.
Animals were divided into the following groups.
C group (n  7). The C group was the no-treatment
group; only prosthetic vascular graft was patched with
suturing. For the purpose of setting the conditions for
establishment of prosthetic graft infection and those for
killing the rabbit with the infection, two S aureus groups at
bacterial doses of 1 107 and 2 107 CFUs were set. The
volume of bacterial suspension was set to 0.1 mL.
B1 group (n 6). Bacterial suspension containing 1
107 CFUs was directly applied on the prosthetic vascular
graft after suturing of the prosthetic vascular patch (Fig 1 ,
A), and the posterior peritoneum was closed with suturing.
B2 group (n 7). Bacterial suspension containing 2
107 CFUs was directly applied on the prosthetic vascular
graft similarly.
T group (n 6). The T group was the bacterial infec-
tion  antibiotic-loaded TCP group. Over the patch graft
in the same condition as the B2 group, antibiotic-loaded
TCP was placed in a straddling position and the posterior
peritoneum was closed with suturing (Fig 1 , B).
All animal care complied with the Principles of Labo-
ratory Animal Care and the Guide for the Care and Use of
Laboratory Animals (NIH Publication No. 80-23, revised
1985).
Method of bacterial detection. Four weeks after im-
plantation of the prosthetic vascular graft on the abdominal
aorta, the prosthetic vascular graft, the tissue around the
prosthetic vascular graft, and the arterial blood were col-
lected. Each of collected prosthetic vascular grafts and
tissues around the prosthetic vascular graft was put in a
liquid medium heart infusion broth (2 mL) and stirred with
an automatic mixer for 1 minute. After incubation at 37° C
under 5% CO2 for 6 hours, 100 L each of the heart
infusion broth was directly inoculated over sheep blood
agar (selection medium for bacteria in general) and manni-
tol salt agar (selection medium for S aureus). Arterial blood,
100 L each, was also inoculated similarly. Each agar was
incubated at 37° C under 5% CO2 for 48 hours for aerobic
cultivation. When a colony was found in both sheep blood
agar and mannitol salt agar, the culturing was judged
positive.
Statistical methods
The significance of the differences in the infection
between groups was assessed with Fisher exact test. In the
examination of survival rate, log-rank test was carried out.
Probabilities of less than .05 were considered significant.
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RESULTS
MIC of teicoplanin for S aureus strain
The MIC for teicoplanin for the S aureus was 1.5
g/mL.
In vitro study of slow release of antibiotics
Stability of teicoplanin in aqueous solution. The
activity on days 3, 7, 14, 21, and 28 was almost 100%. The
activity of dissolved teicoplanin was stable for 4 weeks after
being dissolved in distilled water (n  3; Fig 2).
Preparation of TCP. TCP 0.5 g contained 77.4 to
114.8 mg (mean, 94.9  13.6 mg; 89.8  27.2 mg/g of
TCP) of teicoplanin.
In vitro slow releasing test. The concentration of
teicoplanin in the replaced saline solution had been kept
much higher than MIC for S aureus for at least 40 days. The
MIC against this bacteria was 1.5 g/mL, and teicoplanin
was effective for 40 days. The concentration of teicoplanin
on the 40th day was 669 g/mL, which was much higher
than MIC (n  2; Fig 3).
In vivo study on infection of a patch graft
In the C group, the prosthetic vascular graft and the
tissue around the graft collected after 4 weeks in all the
rabbits (n  7) showed negative in culturing on sheep
blood agar and mannitol salt agar. Absence of bacterial
contamination in the prosthetic vascular graft in our model
was confirmed.
In the B1 group (n  6), two animals had posterior
peritoneal abscess and died of rupture of the anastomosis
site at 1 and 4 weeks after operation. Regarding the other
four animals that survived and were killed after 4 weeks,
bacterial culture of the prosthetic vascular graft and the
tissue around it was positive in two animals and negative in
the other two animals.
In the B2 group (n  7), four animals had posterior
peritoneal abscess and died of rupture of the anastomosis
Fig 1. A, Implanted graft before placement of TCP. B, Antibiotic-loaded TCP was placed straddling over patch
graft.
Fig 2. Activity of dissolved teicoplanin.
Fig 3. Teicoplanin concentration with in vitro study.
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site at 1 and 4 weeks after operation. The other three were
killed at 4 weeks after the operation. Bacterial culture of the
prosthetic vascular graft and the tissue around it was posi-
tive in all the animals.
In the T group, all the animals (n  6) survived for 4
weeks until they were killed. Bacterial cultures of prosthetic
vascular graft and the tissue around it were negative (Ta-
ble). TCP showed a little degradation and some degree of
adhesion with the graft at the time of death.
In bacterial culture of arterial blood, negative results
were obtained in all the animals in the C, B, and T groups.
Infection rate, mortality rate, and cumulative survival
curve
A significant difference in the infection rate was found
between the B2 group and the T group (Fisher exact
probability test, P  .0006). Although no significant dif-
ference in the mortality rate was found between the B2
group and the T group (Fisher exact probability test, P 
.0699; Table), a significant difference was found between
the B2 group and the T group in the cumulative survival
curve (log-rank test, P  .039; Fig 4).
DISCUSSION
There are many problems to be solved in preventions or
treatments of prosthetic vascular graft infection. One of the
causes of graft infection is microorganism contamination of
the graft during implantation or in the perioperative peri-
od.3 On the other hand, in surgical operation, local admin-
istration of antibiotics for prevention of infection in the
operating field has been performed for a long time, but
there has been no clear evidence for its efficacy.24 In the
treatment of experimental wound infection model, Ber-
gamini et al25 reported that in the case of high levels of
bacterial contamination, systemic treatment together with
local application of antibiotics was effective. In the patients
with peripheral vascular surgery, Pitt et al26 reported that
local treatment with antibiotics was as effective as systemic
administration of antibiotics for incision of the inguinal
region.
Therefore, it would be expected that a slow-releasing
DDS of antibiotics could be effective in prophylaxis of
surgical wound infection, when there would be any con-
tamination during surgery. In 1970, Buchholz and En-
gelbrecht27 introduced methylmethacrylate mixed with
penicillin or others in the field of orthopedic surgery as
DDS. Local prevention of vascular grafts was introduced
from the 1980s as studies of extension of local prevention in
orthopedic infection: 1, gentamicin beads12-15; 2, biode-
gradable polymer microspheres8,9; 3, GCS10,11; 4, multive-
sicular liposome-encapsulated amikacin7; and 5, antibiotic-
bonding vascular graft.4-6 Reports on clinical cases
pertaining to gentamicin beads stated that they were re-
quired to be pulled out after a certain period.12,15 Ney et al8
reported that the effect of biodegradable polymer micro-
spheres lasted for only 2 weeks. Jorgensen et al10 and
Holdsworth11 reported that GCS was clinically effective,
but they did not describe the effective period of GCS. As to
multivesicular liposome-encapsulated amikacin, with poly-
tetrafluoroethylene interposition graft in the surgical field
that was experimentally contaminated with 1  105 CFU
of S aureus, Huh et al7 reported improved survival with
decreased postoperative graft infection in 2 weeks of obser-
vation period.
Another way to prevent graft infection is to use the
infection-resistant vascular prosthesis, such as antibiotic-
bonding polytetrafluoroethylene4 and the rifampin-bond-
ing Dacron graft.5 Those grafts have some advantages in
that antibiotics are bonded together with them and any
shape of the graft may be available. Although there has been
no definite answer how long activity of antibiotics should
last to prevent the graft infection, their overall duration of
antibiotic activity was reported to be 2 to 22 days.5 In our
procedure, MIC was maintained for at least 40 days with
teicoplanin to which methicillin-resistant S aureus was sen-
sitive. And the rifamin-bonding Dacron graft was specific
with collagen and rifampin interrelation, which limited the
selection of antibiotics to rifampin so far.5,6 However, our
procedure made a wide selection of antibiotics possible, as
far as antibiotics are stable in a dissoluble condition. TCP
available now does not fit a long prosthetic graft. However,
it may fit some kinds of grafts with processing TCP.
Fig 4. Cumulative survival curve of rabbits in each group.







Alive Dead Positive Negative
C n  7 7 0 0 7
B1 n  6 4 2 4 2




T n  6 6 0 0 7
C group: no-treatment group; B1 group: bacterial suspension containing
1  107 cfu; B2 group: bacterial suspension containing 2  107 cfu; T
group: bacterial infection  antibiotic-loaded TCP group.
*P  .0699.
†P  .0006.
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The porous apatite ceramic, a type of the porous and
biodegradable cement,28,29 was reported as a DDS in
which MIC was maintained at least 40 days.30 Cutright et
al29 reported that degradation of this ceramic was approx-
imately 95% within the 48-day duration without any in-
flammation.28 Hydroxyapatite block (HA-b) and TCP,
porous apatite ceramic, were reported as a carrier of DDS.
Moreover, it was reported that TCP could contain larger
amount of drugs than HA-b and that it could release drugs
more than HA-b after a certain period because TCP might
be higher in porosity and larger in pore size than HA-b.16
Also, TCP was biodegradable and had a homogenous pore
size in a certain range (100 to 400 m).
In this study, teicoplanin was loaded 89.8  27.2
mg/g of TCP and maintained concentrations much higher
than MIC for S aureus for at least 40 days in an in vitro
study. Also, the toxicity of teicoplanin was not so severe
that no animals with teicoplanin-loaded TCP were found
dead 4 weeks after implantation of the graft. S aureus was
used in this study because S aureus was reported to cause
one fourth to one half of cases with graft infections in the
treatment for vascular diseases in the abdominal aorta and
distal to it.3
As an antibiotic, teicoplanin was reported to be highly
effective against S aureus.31-33 In this study, teicoplanin
was used because it was stable after dissolution in saline
solution and effective against S aureus (Gifu 12173) with
MIC of 1.5 g/mL in the E test. Also, it maintained MIC
even after 4 weeks.
An experiment for determination of the appropriate
dose of bacteria was carried out for 4 weeks after implanta-
tion of the prosthetic vascular graft in rabbits. With 1 107
CFU of S aureus, prosthetic vascular graft infection was
established in 67% and death rate from infection was 33%.
When the amount of S aureus was increased to 2  107
CFU, prosthetic vascular graft infection was established in
all the rabbits and 57% died from the infection. The pros-
thetic vascular grafts in the remaining three rabbits were
also infected. Therefore, 2  107 CFU, with which pros-
thetic vascular graft infection was established in all the
rabbits, was used as the dose of S aureus in this study.
In the T group, in which teicoplanin-loaded TCP was
placed around the prosthetic vascular graft contaminated
with S aureus, no death was found during the 4-week
period. Bacterial cultures of the prosthetic vascular graft
and of tissues around it on the 28th day after implantation
were negative in all the rabbits. Our bacterial dose was 2
107 CFU, and the dose was more than that in the liposome-
encapsulated amikacin experiment by Huh et al.7 With this
bacterial dose, the mortality rate of rabbits in 4 weeks was
57%, and the rate of infection of the prosthetic vascular
graft was 100% in our study. This infection was prevented
with teicoplanin-loaded TCP in all the rabbits with 4 weeks
observation.
Therefore, this study suggested that teicoplanin-loaded
TCP may be useful in avoiding Dacron graft infection with
S aureus in rabbits.
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